Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Mesothelioma Early Detection by VOCs (MED-VOC)

Primary Outcome Measures VOC markers in breath samples. Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the early detection of pleural Mesothelioma in patients exposed to asbestos. [ Time Frame: By March 31, 2021 ]Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the ... [More >>]

Phase I Trial HIPEC With Nal-irinotecan

Primary Outcome Measures Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 12 weeks post surgery ]To assess the safety and feasibility of administering nanoliposmal irinotecan intraperitoneally following cytoreductive surgery. Secondary Outcome Measures Plasmatic dosages [ Time Frame: 48 hours ]Determine the correlation of intraperitoneal dosages of nanoliposomal irinotecan with plasma blood levels ... [More >>]

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER)

Primary Outcome Measures Maximum Tolerated Dose for Background Radiation [ Time Frame: Up to five years ]AEs will be graded by CTCAE. Maximum tolerated dose is the dose level that do not result in fatal lung injury (grade 5 lung toxicity) or life-threatening or fatal treatment related toxicity (grade 4+). Secondary Outcome Measures Patient Morbidity [ Time Frame: Up to ... [More >>]

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Primary Outcome Measures Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 5.5 years ]Incidence of treatment-emergent serious adverse events (TESAEs) [ Time Frame: Up to 5.5 years ]Incidence of drug-related TEAEs [ Time Frame: Up to 5.5 years ]Incidence of drug-related TESAEs [ Time Frame: Up to 5.5 years ] Secondary Outcome Measures Overall survival [ Time Frame: Up to 5.5 years ] Inclusion Criteria Participants ongoing in an applicable Bayer-sponsored anetumab ... [More >>]

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Primary Outcome Measures Objective response rate [ Time Frame: Every 6 weeks until disease progression ]Proportion of subjects receiving at least 1 cycle of study therapy and who have had their disease reevaluated that experience partial or complete response per RECIST 1.1 or modified RECIST criteria Inclusion Criteria Male and female participants who are at least 18 ... [More >>]

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Primary Outcome Measures Maximum tolerated dose [ Time Frame: up to 24 months ]A dose will be considered tolerable if there are no more than 2 out of 10 participants with dose limiting toxicities. Inclusion Criteria Age >/= 18 yearsKarnofsky performance status >/= 70%Pathologic diagnosis of malignant pleural mesothelioma at MSKPositive immunohistochemical staining for WT-1Patients must have ... [More >>]

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis (COCOON)

Primary Outcome Measures Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire [ Time Frame: 90 days ]State anxiety reflects the current emotional state, which allows the patient's nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety). The ... [More >>]

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Primary Outcome Measures Objective response rate (ORR) [ Time Frame: 3 months-2 years ]Percentage of subjects with complete or partial response Secondary Outcome Measures duration of response (DUR) [ Time Frame: up to 2 years ]measured from first observation of response to disease progressionprogression free survival (PFS) [ Time Frame: up to 2 years ]measured from start of study to date of progression or death Other ... [More >>]

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Primary Outcome Measures The incidence and characteristics of adverse events, associated with ascending doses of Nap in combination with a set dose of durvalumab [ Time Frame: From day 1 up to 90 days following last dose of study drug ]Number of participants with infusion reactions (e.g. fever, chills, hypotension, tachycardia etc.), occurrence of any ... [More >>]

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Primary Outcome Measures Phase 1a: To assess safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD), and/or recommended dose for expansion (RDE) to Phase 1b. [ Time Frame: From the date of the first dose until 30 days after discontinuation of study treatment. ]The safety and tolerability will be based on Incidence ... [More >>]

Last update: May 07, 2019. 08:38:48 pm.